Medivir, a Swedish research-based pharmaceutical company that focuses on developing treatments for infectious diseases and cancer, has reorganised its management team ‘to streamline and increase operational focus’.
The management team has been reduced from eight to six people and two new functions have been created: Strategic Business Development, which is a consolidation of Corporate Development and Business Development, and Finance & Administration, which is a amalgamates the current Finance & Administration function with Corporate Affairs & IR.
Chief Executive Niklas Prager said he wanted to create ‘a smaller and more effective management team with fewer and stronger functions’.
Christine Lind has been recruited as the new head of Strategic Business Devel-opment, while the new CFO, with responsibility also for IR, will be Ola Burmark.
Christina Kassberg, Rein Piir, Paul Wallace and Håkan Wallin have chosen to leave the company by the end of February.
The new organisation will be effective on 1 March.
